Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...
Zongertinib received FDA approval for HER2-mutant NSCLC, showing efficacy in first-line treatment with a 77% objective ...
Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their ...
An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback